2010, Atrial Flutter and Tachycardia

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2010

Atrial Flutter

Tachycardia

Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2024

Abstract Background Dofetilide is a class III antiarrhythmic agent approved for the treatment of atrial fibrillation and atrial flutter. Given the efficacy of other class III agents, it has been used off-label for the treatment of premature ventricular complexes (PVCs) and ventricular tachycardias (VTs). months ( p <.001).

Tachycardia

Tachycardia Heart Disease Atrial Flutter Heart Transplant

Emergency Department Syncope Workup: After H and P, ECG is the Only Test Required for Every Patient.

Dr. Smith's ECG Blog

APRIL 8, 2015

If the patient has Abnormal Vital Signs (fever, hypotension, tachycardia, or tachypnea, or hypoxemia), then these are the primary issue to address, as there is ongoing pathology which must be identified. J Am Coll Cardiol, 2010; 55:713-721, doi:10.1016/j.jacc.2009.09.049 The tracings were considered abnormal in the following cases: 1.

Arrhythmia

Arrhythmia Outcomes Chest Pain Risk Factors

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Cardiovascular Update

Dofetilide for the treatment of premature ventricular complexes and ventricular tachycardia in patients with structural heart disease

Emergency Department Syncope Workup: After H and P, ECG is the Only Test Required for Every Patient.

Webinars

Stay Connected